Dr. Tripathy on the Development of Palbociclib in Breast Cancer

Article

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Recent Videos
woman in front of a blue background with dark hair
Related Content
light blue background with a white outline indicating breast tissue

Inavolisib Combo Improves Survival in Advanced Breast Cancer

Courtney Flaherty
February 1st 2025
Article

Inavolisib in combination with palbociclib and fulvestrant improved overall survival compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Opinion: Chromosomal Abnormalities in Healthy Breast Tissue May Be Early Indicators of Cancer Risk

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
December 23rd 2024
Article

Oncology nurses can educate patients on the implications of these findings

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

PARP inhibitor

Neoadjuvant Niraparib/Dostarlimab Combo May Yield pCRs in BRCS+, ER+/HER2- Breast Cancer

Ariana Pelosci
December 19th 2024
Article

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

circulating tumor DNA

Study Supports Role of ctDNA in Predicting Outcomes in HR+ Early Breast Cancer

Ashley Chan
December 17th 2024
Article

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.